Patients must have measurable disease as defined by RECIST v. 1.1 criteria; baseline measurements and evaluation of ALL sites of disease must be obtained within 4 weeks prior to registration
One or more metastatic tumors measurable per RECIST Criteria
Measurable disease as per RECIST v1.1 criteria
Must have measurable disease per RECIST v1.1 Response Criteria
Measurable disease by RECIST 1.1 criteria
Subject has measurable disease according to RECIST v1.1 criteria prior to lymphodepletion
Have measurable or non-measurable disease per RECIST 1.1 criteria for solid tumors and RANO criteria for HGG
Measurable tumor lesions according to RECIST 1.1 criteria (Section 10.2).
Measurable disease by RECIST 1.1 criteria
Measurable disease as per RECIST v1.1 criteria
Patients must have at least 1 measurable metastatic lesion by RECIST1.1 criteria
Measurable disease, defined as per RECIST 1.1 criteria
Have measurable disease per RECIST 1.1 criteria present
Measurable disease by per RECIST 1.1 criteria; radiographic tumor assessment performed within 28 days of registration.
All patients enrolled will be required to have measurable disease by RECIST 1.1 criteria
Subject has measurable disease according to RECIST v1.1 criteria prior to lymphodepletion
New or increasing non-bone disease (RECIST 1.1 criteria);
Measurable disease by RECIST 1.1 criteria
Patients must have measurable disease by RECIST criteria
Subject has measurable disease according to RECIST v1.1 criteria prior to lymphodepletion.
Have measurable disease per RECIST 1.1 criteria present
Have measurable disease per RECIST 1.1 or irRECIST criteria present
Measurable disease as per the RECIST criteria v 1.1
Measurable disease according to PET Response Criteria, with the exception of patients with cutaneous disease that can be measured and followed by RECIST criteria
REGORAFENIB INCLUSION CRITERIA: Measurable disease by RECIST v1.1
ENTRECTINIB INCLUSION CRITERIA: Measurable disease by RECIST v1.1
Measurable disease as defined by RECIST v1.1 criteria. Baseline measurements and evaluation of ALL sites of disease must be obtained within 4 weeks prior to Enrollment.
Measurable disease as defined by RECIST 1.1 Criteria.
Measurable tumor lesions according to RECIST 1.1 criteria.[22]
Measurable tumor lesions according to RECIST 1.1 criteria.
Patients must have at least one measurable lesion per RECIST 1.1 criteria.
Patients must have measurable disease by the Modified RECIST criteria
Measurable disease defined by RECIST criteria
Patients must have measurable disease as defined by RECIST 1.1 criteria
Measurable disease as per RECIST 1.1 criteria.
Patients must have measurable disease per RECIST 1.1 criteria; all sites of disease must be evaluated within 4 weeks prior to randomization
Patients must measurable disease, as defined by RECIST 1.1 criteria
Measurable disease per RECIST 1.1 criteria
Have measurable disease per RECIST 1.1 criteria
Measurable disease according to RECIST 1.1 criteria.
Measurable disease by RECIST 1.1 criteria
Measurable disease is required for Part B expansion cohorts according to RECIST v1.1 criteria.
Progressive measurable disease: using conventional solid tumour criteria RECIST 1.1.
Disease must be measurable by RECIST 1.1 criteria
Subjects must have measurable disease by CT or MRI per RECIST 1.1 criteria (radiographic tumor assessment performed within 28 days of first dose of study drug) or clinically apparent disease that the investigator can follow for response per RECIST 1.1
Measurable disease per RECIST 1.1 criteria
Participants must have measurable disease by RECIST 1.1 criteria
Measurable non-CNS disease, defined by RECIST 1.1 criteria
Measurable disease as assessed by RECIST 1.1 criteria (Appendix A).
Measurable disease as defined by RECIST 1.1 criteria;
Measurable disease as assessed by modified RECIST for MPM and by RECIST 1.1 criteria for peritoneal mesothelioma, NSCLC, uveal melanoma, HCC, glioma and sarcomatoid carcinoma
Measurable disease by RECIST 1.1 criteria
Presence of at least one measurable lesion per RECIST 1.1 criteria
Measurable disease as defined by RECIST Criteria.
Measurable disease as defined by RECIST 1.1 criteria
Measurable disease by RECIST 1.1 criteria
Participants in the Phase II portion of the trial must have measurable disease by RECIST 1.1 criteria
Breast cancer participants must have measurable disease by RECIST criteria
For the Extension cohorts, patients must have measurable disease by RECIST criteria and meet the following disease-specific criteria:
Patients must have measurable disease (at least one measurable lesion) as defined by RECIST criteria; all sites of disease must be evaluated within 4 weeks prior to registration to treatment
Measurable disease by CT or MRI per RECIST 1.1 criteria
Measurable disease by RECIST 1.1 criteria.
Measurable disease at screening by RECIST 1.1 criteria
Patients must have measurable disease defined by RECIST criteria 1.1.
Measurable disease by RECIST v1.1 criteria
Measurable tumor lesions according to RECIST 1.1 criteria.[50]
Measurable disease as assessed by RECIST 1.1 criteria (Appendix A).
Have one or more metastatic tumors measurable on CT scan or locally advanced measurable disease that has clearly progressed after prior treatment per RECIST criteria.
Measurable disease by RECIST 1.1 criteria
Measurable disease as assessed by RECIST 1.1 criteria (Appendix A).
Measurable disease on baseline imaging per RECIST 1.1 criteria
Patients must have measurable disease by RECIST 1.1 criteria
Measurable disease, as defined by RECIST 1.1 criteria;
Subject has measurable disease according to RECIST v1.1 criteria.
Measurable disease per RECIST 1.1 criteria
Measurable disease according to RECIST v1.1 criteria
Measurable disease by RECIST criteria
Measurable disease according to RECIST 1.1 criteria.
Measurable disease as per RECIST v1.1 criteria